Low Prevalence of Liver Disease but Regional Differences in HBV Treatment Characteristics Mark HIV/HBV Co-Infection in a South African HIV Clinical Trial

• Prudence Ive,

  Affiliation Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

  ⨯
• William MacLeod,

  Affiliations Health Economics and Epidemiology Research Office, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, Center for Global Health and Development, Boston University, Boston, Massachusetts, United States of America, Department of International Health, Boston University School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Nompumelelo Mkumla,

  Affiliation Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

  ⨯
• Catherine Orrell,

  Affiliation Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa

  ⨯
• Ute Jentsch,

  Affiliation School of Pathology and Wits Health Consortium, Johannesburg, South Africa

  ⨯
• Carole L. Wallis,

  Affiliation Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

  ⨯
• Wendy Stevens,

  Affiliation Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

  ⨯
• Robin Wood,

  Affiliation Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa

  ⨯
• Ian Sanne,

  Affiliation Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

  ⨯
• Debika Bhattacharya

  * E-mail: debikab@mednet.ucla.edu

  Affiliation David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯